Research assistant at Centro de Investigación Biomédica de Occidente, Mexico
Dr. Irving Jair Lara Navarro is a Mexican researcher specializing in genetics and molecular biology. Born on December 9, 1990, in Guadalajara, Jalisco, he has dedicated his career to advancing genetic research, particularly in gene therapy. His work integrates molecular diagnostics, biotechnology, and clinical applications, making significant contributions to biomedical sciences. With a passion for teaching and research, he has been actively involved in academia and laboratory settings, working to bridge the gap between fundamental genetics and medical applications. Dr. Lara Navarro has played a key role in developing innovative approaches for genetic modification, particularly using CRISPR/Cas9 technology. His expertise extends to epidemiological surveillance, laboratory diagnostics, and academic instruction. Throughout his career, he has collaborated with various research institutions, healthcare professionals, and academic institutions, fostering a multidisciplinary approach to genetics. His commitment to scientific excellence and education continues to drive his contributions to the field.
Professional Profile
Education
Dr. Irving Jair Lara Navarro pursued his academic journey in biological sciences, earning a Bachelor’s degree in Biology from the University of Guadalajara (CUCBA) in 2014. His undergraduate research focused on optimizing transduction conditions in keratinocytes using lentiviral vectors. Continuing his passion for genetics, he pursued a Doctorate in Human Genetics at the University of Guadalajara (CUCS), completing it in 2024. His doctoral research revolved around gene therapy using CRISPR/Cas9 technology for modifying the F9 gene in human mesenchymal cells, aiming to enhance the production of Factor IX, a crucial protein for blood clotting. This work has potential therapeutic applications, particularly in treating hemophilia. His academic training has provided him with expertise in molecular biology, genetic engineering, and biomedical research. His strong foundation in experimental design and genetic modifications has positioned him as a key researcher in the field of gene therapy and molecular medicine.
Professional Experience
Dr. Lara Navarro has gained extensive professional experience in research and academia. From 2020 to 2021, he worked as a Research Technician at the Mexican Institute of Social Security (IMSS), contributing to nucleic acid extraction and molecular diagnostics in epidemiological surveillance. He later joined Laboratorio Biodiagnóstica in 2021, where he worked as a Molecular Biology Laboratory Technician, managing laboratory operations, coordinating research teams, and implementing molecular analysis techniques. In addition to his laboratory roles, he has been actively involved in teaching. He served as an Adjunct Professor at Tecmilenio University (Zapopan) from 2021 to 2022, teaching basic sciences at the high school level. Since 2023, he has been a faculty member at Universidad Guadalajara Lamar, where he teaches genetics and biomolecular sciences to medical students. His combined experience in laboratory research and academia has strengthened his ability to contribute to both scientific discovery and education.
Research Interests
Dr. Lara Navarro’s primary research interests lie in genetic engineering, molecular biology, and gene therapy. His doctoral research on CRISPR/Cas9-based gene modification for Factor IX production highlights his focus on therapeutic applications of molecular genetics. He is particularly interested in genetic therapies for hematological disorders, biotechnology applications in medicine, and the development of precision medicine approaches. His expertise in nucleic acid manipulation and viral vector systems contributes to advancements in personalized genetic treatments. Additionally, he has a keen interest in molecular diagnostics and epidemiological surveillance, particularly in developing genetic testing methodologies for disease prevention and treatment. As a researcher, he aims to explore the potential of stem cell therapy, regenerative medicine, and CRISPR-based genome editing for clinical applications. His work aims to bridge the gap between fundamental genetic research and practical medical solutions, contributing to cutting-edge advancements in biomedical sciences.
Awards and Honors
While Dr. Lara Navarro has demonstrated exceptional expertise in genetics and molecular biology, his professional journey is still evolving in terms of formal recognitions. His research in CRISPR/Cas9 gene therapy holds significant potential for future awards and funding opportunities. As an emerging scientist, he has been recognized for his contributions to molecular diagnostics and epidemiological research at IMSS, where he played a crucial role in laboratory procedures during the COVID-19 pandemic. His involvement in academia and research has earned him respect within the scientific and medical communities. While he may not yet have received high-profile research awards, his work on genetic modifications and biomedical applications positions him as a strong candidate for future honors in genetics, biotechnology, and medical research. With continued research output and publications, he is likely to receive formal recognition for his contributions to the field of genetic engineering and molecular medicine.
Conclusion
Dr. Irving Jair Lara Navarro has a strong foundation in genetics, molecular biology, and research methodologies, making him a promising candidate. However, to be a strong contender for the Best Researcher Award, he should focus on publishing in high-impact journals, securing research funding, and increasing international recognition. If these aspects are addressed, he would be a more competitive candidate for the award.
Publications Top Noted
- CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy
- Authors: Lara-Navarro, I.J., Jave-Suárez, L.F., Marchal, J.A., Jaloma-Cruz, A.R.
- Year: 2024
- Journal: Life
- Citations: 0
- Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives
- Authors: Lara-Navarro, I.J., Jaloma-Cruz, A.R.
- Year: 2022
- Journal: Tohoku Journal of Experimental Medicine
- Citations: 3
- Genetic analysis for carrier diagnosis in hemophilia A and B in the Mexican population: 25 years of experience
- Authors: González-Ramos, I.-A., Mantilla-Capacho, J.-M., Luna-Záizar, H., Evangelista-Castro, N., Jaloma-Cruz, A.R.
- Year: 2020
- Journal: American Journal of Medical Genetics, Part C: Seminars in Medical Genetics
- Citations: 5
- Molecular thrombophilic profile in Mexican patients with idiopathic recurrent pregnancy loss
- Authors: López-Jiménez, J.J., Porras-Dorantes, Á., Juárez-Vázquez, C.I., Lara-Navarro, I.J., Jaloma-Cruz, A.R.
- Year: 2016
- Journal: Genetics and Molecular Research
- Citations: 19
- Two girls with a de novo Xq rearrangement of paternal origin: T(X;9)(q24;q12) or rea(X)dup q
- Authors: Vásquez-Velásquez, A.I., Rivera, H., Castro, A.G., Mendoza-Pérez, P., García-Ortiz, J.E.
- Year: 2016
- Journal: Taiwanese Journal of Obstetrics and Gynecology
- Citations: 0
- A further inv dup/del 9p de novo rearrangement. Reappraisal of 25 instances
- Authors: Lara-Navarro, I.J., Córdova-Fletes, C., García-Ruiz, A., Rivera, H.
- Year: 2015
- Journal: Gene Reports
- Citations: 0